HK1149176A1 - Vaccines against multiple subtypes of influenza virus - Google Patents

Vaccines against multiple subtypes of influenza virus

Info

Publication number
HK1149176A1
HK1149176A1 HK11103561.0A HK11103561A HK1149176A1 HK 1149176 A1 HK1149176 A1 HK 1149176A1 HK 11103561 A HK11103561 A HK 11103561A HK 1149176 A1 HK1149176 A1 HK 1149176A1
Authority
HK
Hong Kong
Prior art keywords
influenza virus
vaccines against
against multiple
multiple subtypes
subtypes
Prior art date
Application number
HK11103561.0A
Other languages
English (en)
Chinese (zh)
Inventor
‧德拉奇亞-阿科利
‧韋納
嚴健
‧雷蒂
Original Assignee
賓夕法尼亞大學托管會
製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賓夕法尼亞大學托管會, 製藥有限公司 filed Critical 賓夕法尼亞大學托管會
Publication of HK1149176A1 publication Critical patent/HK1149176A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK11103561.0A 2007-11-12 2011-04-07 Vaccines against multiple subtypes of influenza virus HK1149176A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98728407P 2007-11-12 2007-11-12
PCT/US2008/083281 WO2009073330A2 (en) 2007-11-12 2008-11-12 Novel vaccines against multiple subtypes of influenza virus

Publications (1)

Publication Number Publication Date
HK1149176A1 true HK1149176A1 (en) 2011-09-30

Family

ID=40718429

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103561.0A HK1149176A1 (en) 2007-11-12 2011-04-07 Vaccines against multiple subtypes of influenza virus

Country Status (10)

Country Link
US (4) US9592285B2 (xx)
EP (1) EP2217064A4 (xx)
JP (5) JP5705545B2 (xx)
KR (1) KR101255419B1 (xx)
CN (1) CN101877965B (xx)
AU (1) AU2008331673B2 (xx)
CA (1) CA2705461A1 (xx)
HK (1) HK1149176A1 (xx)
MX (2) MX2010005229A (xx)
WO (1) WO2009073330A2 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008331673B2 (en) 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
BRPI0914224A2 (pt) 2008-06-19 2019-09-24 Variation Biotechnologies Inc composições e métodos para tratar a gripe
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
KR20210149203A (ko) * 2009-11-02 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
US8298820B2 (en) * 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
CN101892248B (zh) * 2010-04-29 2012-04-18 王世霞 禽流感h5 ha抗原的单克隆抗体
WO2012036993A1 (en) * 2010-09-14 2012-03-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
JP6153473B2 (ja) * 2011-02-11 2017-06-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｂ型肝炎ウイルスコアタンパク質をコードする核酸分子およびそれを含むワクチン
KR20140047069A (ko) * 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 ｈ１ｎ１ 인플루엔자를 위한 항원
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
WO2013119683A1 (en) * 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
WO2013122827A1 (en) 2012-02-13 2013-08-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
BR112014023900A2 (pt) * 2012-03-30 2020-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polipeptídeo de hemaglutimina de influenza recombinante, molécula de ácido nucleicoisolada, vetor, célula isolada, partícula semelhante ao vírus da influenza, proteína de fusão, composição, e uso
CN104619719A (zh) * 2012-04-10 2015-05-13 宾夕法尼亚大学理事会 人呼吸道合胞病毒共有抗原、由其制备的核酸构建体和疫苗及其使用方法
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CA2891682A1 (en) 2012-11-27 2014-06-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
JP6307690B2 (ja) * 2012-12-05 2018-04-11 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． アミン誘導体、有機発光材料及びそれを用いた有機エレクトロルミネッセンス素子
US10232030B2 (en) 2013-03-12 2019-03-19 Inovio Pharmaceuticals, Inc. Vaccines for human papilloma virus and methods for using the same
CN110055265A (zh) * 2013-03-15 2019-07-26 宾夕法尼亚大学理事会 针对多种登革病毒亚型的新疫苗
AU2014228497B2 (en) * 2013-03-15 2017-03-02 Inovio Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
CN114045295A (zh) 2013-03-15 2022-02-15 宾夕法尼亚大学理事会 口蹄疫病毒(fmdv)共有蛋白、其编码序列以及由其制造的疫苗
CA2898235A1 (en) 2013-03-15 2014-09-25 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN103421843B (zh) * 2013-07-29 2015-12-09 中国农业科学院哈尔滨兽医研究所 编码h5n1亚型禽流感同义血凝素(ha)蛋白以及同义神经氨酸酶(na)蛋白的基因及其应用
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN106039303A (zh) * 2016-06-20 2016-10-26 华南农业大学 一种h5亚型禽流感dna疫苗及其制备方法
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
CN111526886A (zh) * 2017-10-27 2020-08-11 国家血清研究所 多基因流感疫苗
JP7329530B2 (ja) * 2018-03-28 2023-08-18 サノフィ パスツール インコーポレイテッド ノイラミニダーゼを含む広範に防御的なワクチン組成物を生成する方法
CA3106400A1 (en) * 2018-07-13 2020-01-16 University Of Georgia Research Foundation Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
US20220072120A1 (en) * 2019-02-08 2022-03-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Nanoparticle-based influenza virus vaccines and uses thereof
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
KR102326037B1 (ko) 2019-04-18 2021-11-12 충북대학교 산학협력단 H5 인플루엔자를 치료 또는 예방하기 위한 펩타이드 및 이를 암호화하는 코돈 최적화 서열, 및 이를 이용한 백신
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
CN113461786B (zh) * 2020-03-30 2022-09-13 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
WO2023019274A1 (en) * 2021-08-13 2023-02-16 Purdue Research Foundation Methods and compositions for vaccination against heterosubtypic influenza viruses using an adenoviral vector leading to enhanced t cell response through autophagy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
JP3701966B2 (ja) 1993-01-26 2005-10-05 ウェイナー，デービッド・ビー 遺伝物質送達のための組成物および方法
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5846806A (en) * 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
ES2255181T3 (es) * 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
WO1999024640A1 (fr) 1997-11-12 1999-05-20 Hitachi, Ltd. Procede de surveillance de corps etrangers dans un dispositif de traitement par plasma
WO2002029088A2 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
AU2002364398A1 (en) * 2001-12-21 2003-07-09 Genpat77 Pharmacogenetics Ag Therapeutic monoclonal anti-TIRC7 antibodies for use in immune related and other diseases
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
EP1499348B1 (en) * 2002-04-26 2014-10-01 MedImmune, LLC Method for producing infectious influenza b virus in cell culture
WO2004041177A2 (en) * 2002-11-04 2004-05-21 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
KR101251902B1 (ko) * 2003-02-25 2013-04-08 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
EP1628749B1 (en) * 2003-05-30 2019-07-31 VGXI, Inc. Devices and methods for biomaterial production
CA2566355C (en) * 2004-05-18 2014-04-15 Vical Incorporated Influenza virus vaccine composition and methods of use
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
WO2006104615A2 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
PL1883701T3 (pl) * 2005-04-29 2012-06-29 Univ Cape Town Ekspresja białek wirusa w roślinach
EP1909829A4 (en) * 2005-07-19 2009-11-11 Dow Global Technologies Inc RECOMBINANT GRIP VACCINES
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
EP1937301B1 (en) * 2005-10-18 2015-04-22 Novavax, Inc. Functional influenza virus like particles (vlps)
CA2642644A1 (en) 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Antiviral agents and vaccines against influenza
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
CA2541872A1 (en) * 2006-04-26 2007-10-26 Institut Pasteur H5 pseudotyped viruses and uses thereof
KR20230042399A (ko) * 2006-07-28 2023-03-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
EP2409727B1 (en) * 2006-10-17 2018-10-03 Inovio Pharmaceuticals, Inc. Electroporation devices for electroporation of cells in mammals
TWI403518B (zh) * 2007-01-23 2013-08-01 Academia Sinica 一種流感疫苗及其使用方法
WO2008124331A1 (en) * 2007-04-03 2008-10-16 Cytogenix, Inc. Novel sequences and dna vaccines against avian flu
AU2008331673B2 (en) * 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
US9540657B2 (en) * 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides

Also Published As

Publication number Publication date
MX2010005229A (es) 2010-11-05
EP2217064A2 (en) 2010-08-18
JP2017210482A (ja) 2017-11-30
EP2217064A4 (en) 2012-10-03
JP2013247962A (ja) 2013-12-12
AU2008331673B2 (en) 2014-12-11
JP5705545B2 (ja) 2015-04-22
US20110305664A1 (en) 2011-12-15
US20170165353A1 (en) 2017-06-15
KR20100096164A (ko) 2010-09-01
JP2015120753A (ja) 2015-07-02
US9592285B2 (en) 2017-03-14
JP6047610B2 (ja) 2016-12-21
JP6195943B2 (ja) 2017-09-13
MX339241B (es) 2016-05-18
CN101877965B (zh) 2014-08-20
AU2008331673A1 (en) 2009-06-11
US20090169505A1 (en) 2009-07-02
JP2016052333A (ja) 2016-04-14
US20180333480A1 (en) 2018-11-22
CN101877965A (zh) 2010-11-03
CA2705461A1 (en) 2009-06-11
KR101255419B1 (ko) 2013-04-17
JP2011506272A (ja) 2011-03-03
WO2009073330A2 (en) 2009-06-11
US8133723B2 (en) 2012-03-13
WO2009073330A3 (en) 2010-01-07
US10076565B2 (en) 2018-09-18
JP6549194B2 (ja) 2019-07-24

Similar Documents

Publication Publication Date Title
HK1149176A1 (en) Vaccines against multiple subtypes of influenza virus
IL262734B (en) Influenza virus suppressant compounds and uses thereof
IL262123A (en) Influenza virus vaccines and their uses
ZA201004688B (en) Novel vaccines against multiple subtypes of dengue virus
EP2118323A4 (en) DETECTION OF INFLUENZA VIRUS
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
HK1143085A1 (en) Low-additive influenza vaccines
HK1199211A1 (en) Influenza virus vaccines and uses thereof
IL196024A0 (en) Influenza vaccine
SI2422810T1 (sl) Influenčno cepivo
EP2091960A4 (en) PEPTIDE VACCINE AGAINST INFLUENZA VIRUS
ZA201103175B (en) Vaccine composition for use against influenza
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
ZA200809056B (en) Influenza virus vaccine
BRPI0821034A2 (pt) Vírus influenza modificado
EP1998814A4 (en) NEW VACCINES AGAINST INFLUENZA M2
EP2117589A4 (en) FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
ZA201100962B (en) Influenza vaccines
EP2327714A4 (en) PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST FLUID VIRUS INFECTION
EP2368899A4 (en) VACCINE AGAINST AVIAN INFLUENZA
EP2310030A4 (en) NOVEL ANTIVIRAL PEPTIDES AGAINST INFLUENZA VIRUSES
HK1177692A1 (zh) 新的流感病毒
EP2240199A4 (en) INFLUENZA VACCINES
ZA200900062B (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191110